FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML

Fludarabine and Cytarabine as Continuous Infusion Plus Idarubicin With Granulocyte-Colony Stimulating Factor (G-CSF) Priming for Patients Younger Than 60 Years With Resistant Acute Myeloid Leukemia

- To determine the feasibility of fludarabine and cytarabine as continuous infusion plus idarubicin with granulocyte-colony stimulating factor priming for patients with resistant acute myeloid leukemia other than acute promyelocytic leukemia

- The feasibility will be evaluated in terms of toxicities, complete remission rate, duration of complete remission, disease-free survival, and overall survival.

Inclusion Criteria:

• Failure to achieve CR after initial induction chemotherapy including standard dose cytarabine.
• Early relapse, occurring after a first CR lasting less than 12 months.
• Patients with multiple relapses will be included.
• Written informed consent must be given.
• 15 and 60 years of age.
• 2 or less by ECOG performance scale.

Exclusion Criteria:

• acute promyelocytic leukemia
• pregnant or lactating